Key result
Cross-neutralizing human anti-poliovirus antibodies bind the cellular receptor CD155 recognition site on serotypes 1 and 2, but have insufficient affinity to effectively neutralize type 3.
Answers are grounded in this paper and cite their sources.
Cross-neutralizing anti-poliovirus antibodies bind the cellular receptor recognition site, suggesting potential for developing a universal neutralizing antibody.
Most structural information about poliovirus interaction with neutralizing antibodies was obtained in the 1980s in studies of mouse monoclonal antibodies. Recently we have isolated a number of human/chimpanzee anti-poliovirus antibodies and demonstrated that one of them, MAb A12, could neutralize polioviruses of both serotypes 1 and 2. This communication presents data on isolation of an additional cross-neutralizing antibody (F12) and identification of a previously unknown epitope on the surface of poliovirus virions. Epitope mapping was performed by sequencing of antibody-resistant mutants and by cryo-EM of complexes of virions with Fab fragments. The results have demonstrated that both cross-neutralizing antibodies bind the site located at the bottom of the canyon surrounding the fivefold axis of symmetry that was previously shown to interact with cellular poliovirus receptor CD155. However, the same antibody binds to serotypes 1 and 2 through different specific interactions. It was also shown to interact with type 3 poliovirus, albeit with about 10-fold lower affinity, insufficient for effective neutralization. Antibody interaction with the binding site of the cellular receptor may explain its broad reactivity and suggest that further screening or antibody engineering could lead to a universal antibody capable of neutralizing all three serotypes of poliovirus.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2013) studied Poliovirus. Cross-neutralizing human anti-poliovirus antibodies was evaluated on Epitope mapping and binding site identification. Cross-neutralizing human anti-poliovirus antibodies bind the cellular receptor CD155 recognition site on serotypes 1 and 2, but have insufficient affinity to effectively neutralize type 3.
Synapse has enriched 10 related papers. Consider them for comparative context: